Perspective Therapeutics Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2026). The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623727-en) on January 12, 2026, and is solely responsible for the information contained therein.